Akari Therapeutics Announces Preclinical Data Of AKTX-101 Shows Anti-Tumor Activity Throughout Multiple Clinically Relevant Urothelial Cancer Preclinical Models

Loading news article.

Akari Therapeutics Announces Preclinical Data Of AKTX-101 Shows Anti-Tumor Activity Throughout Multiple Clinically Relevant Urothelial Cancer Preclinical Models | WAPE

Akari Therapeutics Announces Preclinical Data Of AKTX-101 Shows Anti-Tumor Activity Throughout Multiple Clinically Relevant Urothelial Cancer Preclinical Models

Article summary

Related companies

Comments —